CA3130752C - Proteines de fusion fc du domaine extracellulaire cd80 pour le traitement de tumeurs negatives pour pd-l1 - Google Patents

Proteines de fusion fc du domaine extracellulaire cd80 pour le traitement de tumeurs negatives pour pd-l1

Info

Publication number
CA3130752C
CA3130752C CA3130752A CA3130752A CA3130752C CA 3130752 C CA3130752 C CA 3130752C CA 3130752 A CA3130752 A CA 3130752A CA 3130752 A CA3130752 A CA 3130752A CA 3130752 C CA3130752 C CA 3130752C
Authority
CA
Canada
Prior art keywords
ecd
composition
tumor
fusion molecules
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3130752A
Other languages
English (en)
Other versions
CA3130752A1 (fr
Inventor
Susannah D. Barbee
Thomas Brennan
Barbara Sennino
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Priority claimed from PCT/US2020/019135 external-priority patent/WO2020172482A2/fr
Publication of CA3130752A1 publication Critical patent/CA3130752A1/fr
Application granted granted Critical
Publication of CA3130752C publication Critical patent/CA3130752C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des méthodes de traitement de tumeurs négatives pour PD-L1, les méthodes comprenant l'administration de protéines de fusion comprenant le domaine extracellulaire de la classe humaine de différenciation 80 (CD80) et le domaine de fragment cristallisable (Fc) de l'immunoglobuline humaine G1 (IgG1).
CA3130752A 2019-02-22 2020-02-21 Proteines de fusion fc du domaine extracellulaire cd80 pour le traitement de tumeurs negatives pour pd-l1 Active CA3130752C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962809319P 2019-02-22 2019-02-22
US62/809,319 2019-02-22
US201962815249P 2019-03-07 2019-03-07
US62/815,249 2019-03-07
PCT/US2020/019135 WO2020172482A2 (fr) 2019-02-22 2020-02-21 Protéines de fusion fc du domaine extracellulaire cd80 pour le traitement de tumeurs négatives pour pd-l1

Publications (2)

Publication Number Publication Date
CA3130752A1 CA3130752A1 (fr) 2020-08-27
CA3130752C true CA3130752C (fr) 2026-01-27

Family

ID=

Similar Documents

Publication Publication Date Title
US12589132B2 (en) CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
US10703817B2 (en) System for delivery into XCR1 positive cell and uses thereof
KR20190019144A (ko) Pd-l1 및 lag-3에 결합하는 결합 분자
US20210340214A1 (en) Cd80 extracellular domain fc fusion protein dosing regimens
US11547741B2 (en) Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
CA3146948A1 (fr) Methode permettant d'augmenter la numeration lymphocytaire en utilisant une proteine de fusion d'il-7 dans des tumeurs
US11911441B2 (en) Methods of use of CD24 for the prevention and treatment of leukemia relapse
CA3130752C (fr) Proteines de fusion fc du domaine extracellulaire cd80 pour le traitement de tumeurs negatives pour pd-l1
HK40062334B (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
HK40062334A (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
US20240228578A1 (en) Cd80 extracellular domain fc fusion protein therapy
US20230023174A1 (en) Cd80 extracellular domain fc fusion protein regimens
HK40024980A (en) Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies